Chromogranin A Expression in Patients With Hormone Naïve Prostate Cancer Predicts the Development of Hormone Refractory Disease

Abstract

Chromogranin A expression in prostate cancer biopsies is an independent predictive factor of hormone refractory disease in patients with newly diagnosed prostate cancer on early androgen deprivation therapy. Plasma chromogranin A is also a reliable predictive marker and the predictive significance is maintained over time. These results deserve validation in another data set.